Exchange: NASDAQ·Updated 07:30 PM EST
ACAD logo

ACAD Acadia Pharmaceuticals Inc

$18.79
$0.61
(3.36%)
Today
Closed $18.75
$0.0394
(0.21%)
After Hours
Reported EarningsNov 4
Mkt Cap$3.24B
Vol1.79M

About ACAD

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
75

Extremely Bullish Sentiment

How do you feel about ACAD?

BioRich
$ACAD Sometimes the opportunity presents itself where you just have to buy and ask questions afterwards. Was able to get shares at $15.3869 on the uncertainty gift. Snagged some of $PDSB at $1.07 on their dip, and more of $TGTX at $56.91 before it bounced back. Great day, and let's see what we can discover and recover tomorrow. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
14
theobill325
$ACAD Key Catalysts Behind the Drop While Acadia did not issue a press release today and reported strong Q3 2026 earnings just last week (beating both EPS and revenue estimates on November 4), investor focus is centered on a major legal event: • NUPLAZID Patent Appeal (November 9). On Acadia's Q3 earnings call, analysts highlighted that oral arguments at the U.S. Court of Appeals for the Federal Circuit were scheduled for today, Monday, November 9. Generic drugmaker Aurobindo Pharma is appealing a lower court ruling that upheld Acadia's '721 formulation patent for NUPLAZID 34 mg capsules—a patent that protects exclusivity through 2038. Because NUPLAZID generated $202 million of Acadia's $342 million in Q3 revenue, any perceived judicial skepticism during oral arguments threatens its long-term cash flows. • Technical Breakdown. Once shares broke below the prior 52-week floor of $18.39, automated stop-loss orders and momentum selling appear to have accelerated the drop into the close.
11
raylin
$ACAD Great call. Professional and positive. Sounds like they learned a lot from P2 and will apply to P3.
10
millionaire2021
$ACAD guys anyone here why it’s crating so bad .. got many invested balls deep here !! Don’t know how to get out of this fuss
2
3
BioRich
$ACAD and $CADL, Nice 20+% trades. Still hold a profitable core for $CADL but rolling these swings into cores for $SMMT and $ABCL. Already top 5 holdings (#2 and #4, respectively). Will be fun to watch how this rotation plays out. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers! $XBI
7
StockHunter75
$ACAD Down for no reason, way oversold. Time to load the boat, short sellers will eventually get liquidated.
8
Night_Owl_Biotech
$ACAD trades at meaningfully lower multiples of analyst consensus revenue estimates versus its peer commercial-stage non-oncology focused peers. We will compare ACAD's multiples to its peers in 10-14 days after earnings season has concluded & analyst estimates are updated. For now you simply have to take our word for it. Only $ARDX trades at lower multiples. The attachments compare ACAD's analyst consensus revenue estimates to $APLS as of the date it announced the $BIIB acquisition. APLS was acquired for an enterprise value of roughly $5.6B Note analysts project ACAD's 2 products to generate meaningfully higher revenues than APLS, and at higher gross profit margins, yet ACAD's valuation is meaningfully lower. ACAD's SG&A expense as a % of sales is consistent with its peers We genuinely want to know if any investors can point out the reason for the disconnect. $XBI
8
zeustony88
$ACAD Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference Business Wire · Nov-09-2026 4:05 PM ET SAN DIEGO, Calif.--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (ACAD.NaE) today announced that it will present two data presentations related to Alzheimer's disease psychosis (ADP) and remlifanserin at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place November 16-19, 2026, in Boston. Acadia's presentations include an oral presentation featuring findings from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin in patients with Alzheimer's disease psychosis, as well as a poster presentation examining biomarker heterogeneity among patients meeting clinical criteria for ADP. Collectively, these presentations reflect Acadia's commitment to advancing the understanding and treatment of psychosis associated with Alzheimer’s disease.
7
Ken012
$ACAD RBC Raises Price Target on ACADIA Pharmaceuticals to $38 From $36, Keeps Outperform Rating
7
zeustony88
$ACAD “We continue to believe in the strength of our position on the NUPLAZID formulation patent, on which the Federal Circuit heard oral arguments today,” CEO Catherine Owen Adams noted. “Acadia believes the district court’s decision is supported by the facts established at trial and by applicable law.”
6
Ken012
$ACAD Acadia Pharmaceuticals held oral arguments today regarding its Nuplazid patent, with CEO Catherine Owen Adams expressing confidence in its strength and protection until February 2038.
6
BobBijawklah
$ACAD acadia just had a joint dismisall versus zydus for the same patent question just another generic manufacturer . So that is what i am saying that it would be highly highly unlikely that the new judge would rule against acadia when the lower court ruled in their favor already and another court ruled in favor of acadia versus another generic manufacturer. 90 percent chance the court upholds lower courts ruling , unless the plaintif has paid off the judge
6
BobBijawklah
$ACAD two courts ruled in acadia favor dont believe that the new appeal of the other two courts will result in anything different.
6
Daniech0514
$ACAD Nice earnings call. Great company. Looks like they recently settled their patent case to keep companies Nuplazid exclusivity for 2038. Can someone please explain why the PE ratio is so low? When they have almost $1B cash on hand, and generate over $1B in revenue per year. Some analyst have $30/sh target I think it could be worth $40 But I could be wrong.
6
stockpicker63
💊 $ACAD — Acadia Pharmaceuticals 🔥 BIOTECH GROWTH + UPCOMING CATALYSTS Q3 revenue: $342M, up 23% DAYBUE sales up 39% NUPLAZID sales up 12% Cash and investments: $976M Raised DAYBUE full-year sales guidance Additional Alzheimer's clinical data expected November 17 🟢 Strong product growth and an interesting clinical pipeline. Watch the upcoming clinical data catalyst.
5
zeustony88
$ACAD Canaccord Genuity Maintains Buy on Acadia Pharmaceuticals, Raises Price Target to $38
5
dgbio
$ACAD Whatever it is, it's not about Daybue. Both competitors, Taysha and Neurogene, are not moving.
4
BiotechSwings
nothing hard lands today on the FDA clock tomorrow is Saturday and it is stacked anyway. CYTK gets its aficamten label call from MAPLE HCM, SMMT gets ivonescimab in EGFR lung cancer, plus Igalmi for at home agitation. Saturday dates, so today is the practical window imo next 7 days add $ACAD on Nov 17, detailed Phase 2 remlifanserin data at CTAD in Alzheimer psychosis
3
BobBijawklah
$ACAD LOL the drop was as a result of an appeals court for patent of nuplazid when two other courts already ruled in ACAD favor. How many convicted killers win an appeal. Sure it can happen but 30% for something known. LMAO what would price be if the ruling was overturned. would we drop to 9 dollars a share.?
3
Loosewin
Sold the rest half of my $ACAD shares at $22.45, effectively making $0.85 per share ($1.55 loss per share, offset by $2.40 earned from earlier options trades).
3

Advertisement|Remove ads.